組織蛋白酶L(CTSL)重組蛋白
Recombinant Cathepsin L (CTSL)
CTSL1; CATL; CTS-L; MEP; Cathepsin L1; Major excreted protein
- 編號RPA306Mu01
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位溶酶體
- 預測分子量41.8kDa
- 實際分子量40kDa(差異分析請參閱說明書)
- 片段與標簽Thr18~Lys113 with N-terminal His and GST Tag
- 緩沖液成份PBS, pH7.4, containing 0.05% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 97%
- 等電點7.3
-
應用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1166 ¥ 2916 ¥ 5832 ¥ 17496 ¥ 43740
- 欲了解實際交易價格和更多情況，請與當地經銷商聯系!
-
產品包裝(模擬)
-
產品包裝(模擬)
-
Figure. SDS-PAGE
-
通過ISO 9001、ISO 13485質量體系認證
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩定性
熱穩定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產生。保質期內，在適當的條件下存儲，損失率低于5%。
增值服務
相關產品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA306Mu01 | 組織蛋白酶L(CTSL)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA306Mu02 | 組織蛋白酶L(CTSL)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA306Mu02 | 組織蛋白酶L(CTSL)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA306Mu01 | 組織蛋白酶L(CTSL)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA306Mu71 | 組織蛋白酶L(CTSL)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| SEA306Mu | 組織蛋白酶L(CTSL)檢測試劑盒(酶聯免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA306Mu | 組織蛋白酶L(CTSL)等多因子檢測試劑盒(流式熒光發光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Hypertension | Identification of Cathepsin L as a Potential Sex-Specific Biomarker for Renal Damage. [Ahajournals: source] |
| The Journal of International Medical Research | Plasma Cathepsin L and Its Related Pro/Antiangiogenic Factors Play Useful Roles in Predicting Rich Coronary Collaterals in Patients with Coronary Heart Disease [Ingenta: art00021] |
| Atherosclerosis.? | Biochemical and clinical correlation of intraplaque neovascularization using contrast-enhanced ultrasound of the carotid artery [Pubmed:24534452] |
| International Journal of Molecular Sciences | A New Analytical Method for Determination of Cathepsin L Based on the Surface Plasmon Resonance Imaging Biosensor [Pubmed: 31052424] |
| EMBO Molecular Medicine | Immune‐mediated ECM depletion improves tumour perfusion and payload delivery [Pubmed: 31709774] |
| Cardiovasc Res | Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size [34132807] |
留言咨詢
